Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
BioNTech
About
BioNTech is a biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.
- Mainz,Rheinland-Pfalz,Germany
- 1001 - 5000
- http://www.biontech.de
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $149.99M
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2008
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
- Stock Symbol
- nasdaq:BNTX
- Legal Name
- BioNTech AG
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 14, 2022 | Post-IPO Equity | $149.99M | — | — | — | Detail |
| Sep 15, 2020 | Grant | €375M | 1 |
German Federal Ministry of Education and Research (BMBF)
|
— | Detail |
| Jun 29, 2020 | Post-IPO Equity | $250M | 1 |
Temasek Holdings
|
— | Detail |
| Jun 11, 2020 | Post-IPO Debt | $100M | 1 | — | — | Detail |
| Dec 17, 2019 | Post-IPO Debt | €50M | 1 |
European Investment Bank
|
— | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 7, 2022
Greenforce
|
Series Unknown | €13M | Food and Beverage | — |
|
Nov 30, 2022
Ryvu
|
Post-IPO Equity | €20M | Biotechnology | Yes |
|
Feb 2, 2022
MediGene
|
Post-IPO Equity | €26M | Biotechnology | Yes |
|
Jan 25, 2022
InstaDeep
|
Series B | $100M | Artificial Intelligence | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
German Federal Ministry of Education and Research (BMBF)
|
Yes | Grant |
|
Temasek Holdings
|
Yes | Post-IPO Equity |
Bill & Melinda Gates Foundation
|
Yes | Series Unknown |
Fidelity Management and Research Company
|
Yes | Series B |
Sanofi
|
Yes | Corporate Round |
|
European Investment Bank
|
— | Post-IPO Debt |
Athena Capital (South Africa)
|
— | Series B |
BVCF
|
— | Series B |
Invus
|
— | Series B |
Jebsen Capital
|
— | Series B |
Employee Profiles
Exits
BioNTech has had 3 exits. BioNTech most notable exits include InstaDeep , Ryvu
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Jan 10, 2023 | InstaDeep | M&A | Artificial Intelligence | Detail |
| Jan 4, 2013 | Ryvu | IPO | Biotechnology | Detail |
| Jun 30, 2000 | MediGene | IPO | Biotechnology | Detail |
Acquisition
BioNTech has acquired 3 organizations. Their most recent acquisition was Neon Therapeutics on Jan 16, 2020. They acquired Neon Therapeutics for $67M.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Jan 16, 2020
Neon Therapeutics
|
Bioinformatics | acquisition | $ 67M | Detail |
|
Jul 19, 2021
|
Pharmaceutical | acquisition | — | Detail |
|
Nov 9, 2021
PhagoMed
|
Biopharma | acquisition | — | Detail |
